<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516122</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0353</org_study_id>
    <secondary_id>NCI-2020-05358</secondary_id>
    <secondary_id>2020-0353</secondary_id>
    <nct_id>NCT04516122</nct_id>
  </id_info>
  <brief_title>Bone Loss in Melanoma Survivors Receiving Immunotherapy</brief_title>
  <official_title>Bone Loss in Cancer Survivors Receiving Adjuvant Immune Checkpoint Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the bone-related side effects caused by immunotherapy drugs such as&#xD;
      nivolumab and pembrolizumab in patients with melanoma. Nivolumab and pembrolizumab are&#xD;
      immunotherapy drugs (drugs that boost your immune system) used to prevent cancer from coming&#xD;
      back in patients with melanoma. Specifically, researchers want to learn if there is any&#xD;
      relationship between receiving immunotherapy and bone density (thickness) measured by a&#xD;
      dual-energy X-ray absorptiometry (DXA) scan or bone turnover markers (which indicate levels&#xD;
      of bone loss) found in the blood. This study may provide researchers with more information on&#xD;
      bone loss and may help prevent bone loss in future patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Characterize the effects of adjuvant immune checkpoint inhibitor (ICI) therapy (nivolumab&#xD;
      or pembrolizumab) on measures of bone health, including bone density and bone turnover&#xD;
      markers, in a prospectively recruited cohort of 40 adult patients (&gt;= 40 years) with melanoma&#xD;
      diagnoses seen at MD Anderson Cancer Center.&#xD;
&#xD;
      II. Identify associations of baseline demographic, clinical, and general bone loss risk&#xD;
      factors (e.g., age, corticosteroid use) and tumor characteristics with bone loss in the same&#xD;
      cohort.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo collection of blood samples after starting immunotherapy and then at 6 and&#xD;
      12 months. Patients also undergo DXA scan over 5-10 minutes after starting immunotherapy and&#xD;
      at 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in bone density</measure>
    <time_frame>Baseline up to 6 months after treatment initiation</time_frame>
    <description>Evaluated using dual X-ray absorptiometry (DXA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in done turnover markers</measure>
    <time_frame>Baseline up to 6 months after treatment initiation</time_frame>
    <description>Evaluated in bone turnover markers (serum CTX and BSAP) in the study patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of fractures</measure>
    <time_frame>Baseline to 1.5 years of follow-up</time_frame>
    <description>Will be assessed by review of patient's electronic medical records. Will evaluate the associations of each demographic, clinical, and general bone loss risk factor and tumor characteristic with change in bone density using linear regression models in univariate and multivariate settings. We will also summarize bone fractures descriptively according to the proportion of patients experiencing fractures and the time from treatment initiation to fracture.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Clinical Stage III Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage IV Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage III Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage IIIA Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage IIIB Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage IIIC Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage IIID Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage IV Cutaneous Melanoma AJCC v8</condition>
  <arm_group>
    <arm_group_label>Observational (biospecimen collection, DXA scan)</arm_group_label>
    <description>Patients undergo collection of blood samples after starting immunotherapy and then at 6 and 12 months. Patients also undergo DXA scan over 5-10 minutes after starting immunotherapy and at 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood samples</description>
    <arm_group_label>Observational (biospecimen collection, DXA scan)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dual X-ray Absorptiometry</intervention_name>
    <description>Undergo DXA scan</description>
    <arm_group_label>Observational (biospecimen collection, DXA scan)</arm_group_label>
    <other_name>BMD scan</other_name>
    <other_name>bone mineral density scan</other_name>
    <other_name>DEXA</other_name>
    <other_name>DEXA Scan</other_name>
    <other_name>dual energy x-ray absorptiometric scan</other_name>
    <other_name>Dual Energy X-ray Absorptiometry</other_name>
    <other_name>Dual X-Ray Absorptometry</other_name>
    <other_name>DXA</other_name>
    <other_name>DXA SCAN</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stage III/IV melanoma receiving immune checkpoint inhibitor therapy at MD&#xD;
        Anderson Cancer Center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stage III or IV melanoma with no evidence of disease following resection according to&#xD;
             the 2009 American Joint Committee on Cancer classification criteria&#xD;
&#xD;
          -  No prior history of osteoporosis or fractures as per medical record review and patient&#xD;
             history&#xD;
&#xD;
          -  Scheduled to begin receiving adjuvant ICI therapy (nivolumab or pembrolizumab)&#xD;
             irrespective of dose or setting&#xD;
&#xD;
          -  Plan to continue care, including ICI infusions, at MD Anderson&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noha Abdelwahab Hassan</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noha Abdelwahab Hassan</last_name>
    <phone>713-794-3232</phone>
    <email>nahassan@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noha Abdelwahab Hassan</last_name>
      <phone>713-794-3232</phone>
    </contact>
    <investigator>
      <last_name>Noha Abdelwahab Hassan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

